Benjamin F. Edwards & Company, Inc. Fate Therapeutics Inc Transaction History
Benjamin F. Edwards & Company, Inc.
- $5.69 Billion
- Q2 2024
A detailed history of Benjamin F. Edwards & Company, Inc. transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Benjamin F. Edwards & Company, Inc. holds 700 shares of FATE stock, worth $1,603. This represents 0.0% of its overall portfolio holdings.
Number of Shares
700
Previous 700
-0.0%
Holding current value
$1,603
Previous $5,000
60.0%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding FATE
# of Institutions
175Shares Held
115MCall Options Held
53.7KPut Options Held
9K-
Redmile Group, LLC San Francisco, CA13.2MShares$30.2 Million3.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.4MShares$23.8 Million0.0% of portfolio
-
Black Rock Inc. New York, NY10.1MShares$23.2 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT5.57MShares$12.8 Million0.72% of portfolio
-
State Street Corp Boston, MA5.25MShares$12 Million0.0% of portfolio
About FATE THERAPEUTICS INC
- Ticker FATE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,000,304
- Market Cap $222M
- Description
- Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...